Patient Square Capital LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001819257

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 23 positions · Total reported value $645.52M · Top-10 concentration 80.1% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 69.0% · 6 new · 8 cut · 6 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

In its Q2 2026 13F filing, Patient Square Capital LP disclosed 23 equity positions with a combined reported value of $645.52M. The filing implies a focused portfolio: its ten largest positions account for 80.1% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were ROIV ($283.86M), RVMD ($51.69M), MIRM ($30.50M). By sector, the heaviest allocations are Health Care 97.7%, Industrials 1.6%. Versus the prior quarter, allocation shifted toward Other (+0.7pp).

Versus the prior quarter, Patient Square Capital LP opened 6 new positions, trimmed 8 and fully exited 6, a turnover rate of 69.0% of positions. The portfolio's overlap with the prior quarter was 49% of names.

The largest new positions opened in Q2 2026 were RVMD ($51.69M), UTHR ($20.11M), BNTX ($12.51M).

Of the 6 positions fully exited versus the prior quarter, the largest were INSM ($25.75M), LEGN ($17.91M), NKTR ($15.11M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • RVMD REVOLUTION MEDICINES INC · $51.69M
  • UTHR UNITED THERAPEUTICS CORP DEL · $20.11M
  • BNTX BIONTECH SE · $12.51M
  • CCCC C4 THERAPEUTICS INC · $7.51M
  • IVA INVENTIVA SA · $7.44M
  • FTH Faeth Therapeutics Inc · $4.38M

Fully Exited (vs previous quarter)

  • INSM INSMED INC · prev qtr: $25.75M
  • LEGN LEGEND BIOTECH CORP · prev qtr: $17.91M
  • NKTR NEKTAR THERAPEUTICS · prev qtr: $15.11M
  • CELC CELCUITY INC · prev qtr: $10.84M
  • MRK MERCK & CO · prev qtr: $9.62M
  • CATX PERSPECTIVE THERAPEUTICS INC · prev qtr: $6.78M
  • DFTX DEFINIUM THERAPEUTICS INC · prev qtr: $6.26M · history
  • HROW HARROW INC · prev qtr: $5.83M · history

Insider Transactions (Form 4)

Latest Patient Square Capital LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Patient Square Capital LP is a Menlo Park, CA-based investment firm founded by David Goel and Stephen Mandel Jr. with approximately $17.5 billion in assets under management.

Investment Approach

They employ a long-term, concentrated investment strategy focusing on high-quality companies with strong competitive advantages.

Asset Classes

Primarily invests in US equities, as evidenced by their SEC Form 13F filings.

Notable Facts

Founded in 2016, known for activist investment style, sometimes taking significant positions in companies and advocating for changes.

Key People

Founded by David Goel and Stephen Mandel Jr. (co-founder of Lone Pine Capital).

For official disclosures, refer to the firm's SEC filings.

AI Rebalance Analysis

1. Overall Direction and Market View: Patient Square Capital LP appears to be maintaining a cautious approach with a slight bias towards healthcare sector. The reduction in positions and the introduction of new ones indicate a reevaluation of the market conditions, possibly reflecting a preference for new opportunities or a conservative stance amidst market uncertainty. 2. Key Moves: - Added: Revolution Medicines Inc (RVMD), Mirum Pharmaceuticals Inc (MIRM), Abivax SA (ABVX), Beone Medicines Ltd (ONC), Pharvaris NV (PHVS), United Therapeutics Corp (UTHR). These additions suggest a focus on potentially undervalued or emerging healthcare companies. - Reduced: ROivant Sciences Ltd (ROIV), Argenx SE (ARGX), Belite Bio Inc (BLTE), Cogent Biosciences Inc (COGT). The reduction in ROIV and ARGX indicates a move away from established but possibly less promising investments, while the reduction in BLTE and COGT could be due to valuation concerns or performance issues. 3. Portfolio Structure: The portfolio appears to be active, with a significant sector bias towards healthcare. The healthcare sector weight of 43.97% in ROIV, the largest holding, indicates a strong commitment to this sector. The fund's risk appetite seems moderate, with a mix of additions and reductions in positions, indicating a balanced approach to portfolio management. 4. Per-Holding One-Liner: - ROIV: ROivant Sciences Ltd - A biopharmaceutical company focusing on developing treatments for rare and orphan diseases. - RVMD: Revolution Medicines Inc - A biopharmaceutical company focusing on novel therapies for cancer and other diseases. - MIRM: Mirum Pharmaceuticals Inc - A biopharmaceutical company specializing in treatments for rare genetic disorders. - ABVX: Abivax SA - A biopharmaceutical company developing treatments for infectious diseases and inflammatory conditions. - ONC: Beone Medicines Ltd - A biopharmaceutical company focused on novel therapies for oncology. - PHVS: Pharvaris NV - A biopharmaceutical company specializing in treatments for rare and orphan diseases. - ARGX: Argenx SE - A biopharmaceutical company focused on developing therapies for autoimmune and inflammatory diseases. - UTHR: United Therapeutics Corp - A biopharmaceutical company specializing in treatments for pulmonary hypertension and other cardiovascular conditions. - BLTE: Belite Bio Inc - A biopharmaceutical company focused on developing treatments for oncology and other diseases. - COGT: Cogent Biosciences Inc - A biopharmaceutical company developing therapies for autoimmune and inflammatory diseases. 5. One-Sentence Style Summary: Patient Square Capital LP maintained its focus on healthcare sector with a cautious rebalancing strategy, adding new investments in emerging biopharmaceutical companies while trimming positions in established players.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 97.7%
Other 0.7%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 8.02M $283.86M 43.97%
43.97%
Reduce
2 276.00K $51.69M 8.01%
8.01%
New
3 260.50K $30.50M 4.72%
4.72%
Add
4 206.50K $27.52M 4.26%
4.26%
Add
5 90.02K $25.65M 3.97%
3.97%
Add
6 671.21K $23.21M 3.60%
3.60%
Add
7 23.00K $21.34M 3.31%
3.31%
Reduce
8 37.12K $20.11M 3.12%
3.12%
New
9 110.00K $16.94M 2.62%
2.62%
Reduce
10 425.00K $16.45M 2.55%
2.55%
Reduce
11 909.47K $14.92M 2.31%
2.31%
Add
12 220.00K $13.28M 2.06%
2.06%
Reduce
13 134.43K $12.51M 1.94%
1.94%
New
14 355.80K $10.97M 1.70%
1.70%
Add
15 212.50K $10.78M 1.67%
1.67%
Add
16 108.00K $10.53M 1.63%
1.63%
Add
17 5.05M $10.50M 1.63%
1.63%
Add
18 720.00K $10.30M 1.59%
1.59%
Reduce
19 370.00K $9.70M 1.50%
1.50%
Reduce
20 1.61M $7.51M 1.16%
1.16%
New
21 1.97M $7.44M 1.15%
1.15%
New
22 47.50K $5.45M 0.84%
0.84%
Reduce
23 175.05K $4.38M 0.68%
0.68%
New

FAQ

What did Patient Square Capital LP buy in 2026-Q2?

In its 2026-Q2 13F filing, Patient Square Capital LP reported 23 equity positions worth $645.52M in aggregate; its largest disclosed positions were ROIV ($283.86M), RVMD ($51.69M), MIRM ($30.50M).

How large is Patient Square Capital LP's portfolio?

Patient Square Capital LP reported $645.52M of long equity holdings across 23 positions as of 2026-Q2. Top-10 holdings account for 80.1% of reported value.

What is Patient Square Capital LP's investment style?

HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/patient-square-capital/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →